AU2018256601A1 - Use of anti-VEGF antibody in combination with chemotherapy for treating breast cancer - Google Patents
Use of anti-VEGF antibody in combination with chemotherapy for treating breast cancer Download PDFInfo
- Publication number
- AU2018256601A1 AU2018256601A1 AU2018256601A AU2018256601A AU2018256601A1 AU 2018256601 A1 AU2018256601 A1 AU 2018256601A1 AU 2018256601 A AU2018256601 A AU 2018256601A AU 2018256601 A AU2018256601 A AU 2018256601A AU 2018256601 A1 AU2018256601 A1 AU 2018256601A1
- Authority
- AU
- Australia
- Prior art keywords
- combination
- breast cancer
- vegf antibody
- chemotherapy
- treating breast
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010006187 Breast cancer Diseases 0.000 title abstract 2
- 208000026310 Breast neoplasm Diseases 0.000 title abstract 2
- 238000002512 chemotherapy Methods 0.000 title 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
OF THE DISCLSOURE This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human subjects susceptible to or diagnosed with breast cancer using an anti-VEGF antibody, 5 preferably in combination with one or more additional anti-tumor therapeutic agents. 10728141_1 (GHMatters) P87074.AU.3
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2018256601A AU2018256601A1 (en) | 2008-11-22 | 2018-11-01 | Use of anti-VEGF antibody in combination with chemotherapy for treating breast cancer |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61/117,102 | 2008-11-22 | ||
| US61/178,009 | 2009-05-13 | ||
| US61/179,307 | 2009-05-18 | ||
| AU2009316409A AU2009316409A1 (en) | 2008-11-22 | 2009-11-20 | Use of anti-VEGF antibody in combination with chemotherapy for treating breast cancer |
| AU2015203013A AU2015203013A1 (en) | 2008-11-22 | 2015-06-05 | Use of anti-VEGF antibody in combination with chemotherapy for treating breast cancer |
| AU2017200300A AU2017200300A1 (en) | 2008-11-22 | 2017-01-17 | Use of anti-VEGF antibody in combination with chemotherapy for treating breast cancer |
| AU2018256601A AU2018256601A1 (en) | 2008-11-22 | 2018-11-01 | Use of anti-VEGF antibody in combination with chemotherapy for treating breast cancer |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2017200300A Division AU2017200300A1 (en) | 2008-11-22 | 2017-01-17 | Use of anti-VEGF antibody in combination with chemotherapy for treating breast cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2018256601A1 true AU2018256601A1 (en) | 2018-11-22 |
Family
ID=53561535
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2015203013A Abandoned AU2015203013A1 (en) | 2008-11-22 | 2015-06-05 | Use of anti-VEGF antibody in combination with chemotherapy for treating breast cancer |
| AU2017200300A Abandoned AU2017200300A1 (en) | 2008-11-22 | 2017-01-17 | Use of anti-VEGF antibody in combination with chemotherapy for treating breast cancer |
| AU2018256601A Abandoned AU2018256601A1 (en) | 2008-11-22 | 2018-11-01 | Use of anti-VEGF antibody in combination with chemotherapy for treating breast cancer |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2015203013A Abandoned AU2015203013A1 (en) | 2008-11-22 | 2015-06-05 | Use of anti-VEGF antibody in combination with chemotherapy for treating breast cancer |
| AU2017200300A Abandoned AU2017200300A1 (en) | 2008-11-22 | 2017-01-17 | Use of anti-VEGF antibody in combination with chemotherapy for treating breast cancer |
Country Status (1)
| Country | Link |
|---|---|
| AU (3) | AU2015203013A1 (en) |
-
2015
- 2015-06-05 AU AU2015203013A patent/AU2015203013A1/en not_active Abandoned
-
2017
- 2017-01-17 AU AU2017200300A patent/AU2017200300A1/en not_active Abandoned
-
2018
- 2018-11-01 AU AU2018256601A patent/AU2018256601A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017200300A1 (en) | 2017-02-02 |
| AU2015203013A1 (en) | 2015-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2010059969A8 (en) | Use of anti-vegf antibody in combination with chemotherapy for treating breast cancer | |
| TNSN05300A1 (en) | Treatment with anti-vegf antibodies | |
| EP3064509A3 (en) | Anti-angiogenesis therapy for the treatment of ovarian cancer | |
| WO2004113571A3 (en) | Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis | |
| EA201070636A1 (en) | INHIBITION OF THE PROTECTOR PROTEIN, STIMULATING MACROPHAGE (RON), AND METHODS OF ITS TREATMENT | |
| TW200806322A (en) | Diagnostics and treatments for tumors | |
| IL184617A0 (en) | Dr5 antibodies and uses thereof | |
| EA201000016A1 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER, TUMORS AND DISTURBANCES ASSOCIATED WITH TUMORS | |
| MX2010001757A (en) | Monoclonal antibody 175 targeting the egf receptor and derivatives and uses thereof. | |
| WO2007109236A3 (en) | Microrna fingerprints during human megakaryocytopoiesis | |
| EA201590833A1 (en) | ANTIBODIES FOR THE TREATMENT AND PREVENTION OF THE ALZGEIMER'S DISEASE AND THEIR APPLICATION | |
| UA106194C2 (en) | Diagnosis and treatment of cancer using anti-ereg antibody | |
| MX2009012625A (en) | Methods of treating, diagnosing and detecting fgf21-associated disorders. | |
| CR11179A (en) | HUMANIZED ANTIBODIES AGAINST AB GLOBOMETER (20-42) AND ITS USES | |
| WO2008003656A3 (en) | Prostate specific transcripts and the use thereof for prostate cancer therapeutics and diagnostics | |
| EP2175879A4 (en) | Treatment of prion protein related diseases | |
| MX2009010269A (en) | Methods of treating cancer by administering human il-18 combinations. | |
| PH12012500296A1 (en) | Anti-angiogenesis therapy for the treatment of previously treated breast cancer | |
| WO2007111661A3 (en) | Human antibodies specific for gastrin materials and methods | |
| MX2018009499A (en) | Egfl6 specific monoclonal antibodies and methods of their use. | |
| WO2006027693A3 (en) | Tumor specific genes and variant RNAS and uses thereof as targets for cancer therapy and diagnosis | |
| EP2294197A4 (en) | Variant hhip1 protein and methods and uses thereof | |
| WO2009091230A3 (en) | Protein marker for breast-cancer monitoring, diagnosis and screening, and a breast-cancer monitoring, diagnosis and screening method using the same | |
| AU2018256601A1 (en) | Use of anti-VEGF antibody in combination with chemotherapy for treating breast cancer | |
| WO2020186111A3 (en) | Vista-binding antibodies and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |